Clinical Impact of 16S rDNA PCR

Clinical Impact of 16S rDNA PCR, a Monocentric Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03915275

Acronym

CI16DP

Enrollment

Registered

2019-04-16

Start date

2019-05-01

Completion date

2020-05-31

Last updated

2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections

Brief summary

The main objective of this study is to evaluate the impact of a positive 16S rDNA PCR in various sites on patient's management. The secondary objectives of the protocol are: * to evaluate bacterial identification performance * to evaluate the effect of previous antibiotic therapy * to analyze the management of discordant results between 16S PCR and culture identification

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Inclusion criteria

* Patients that had a 16S rDNA PCR positive result in Strasbourg University Hospital laboratory from 2014 to 2018 * Patients consent for this analysis of their past medical history * Legal guardians consent for the analysis of their children's medical history

Exclusion criteria

* Patients who express opposition for this study * Incomplete clinical record

Design outcomes

Primary

Measure	Time frame
Study of the modification of the care of the patients by the use of the 16S PCR	The period from Junuary 1st, 2014 to Dcember 31, 2018 will be examined

Countries

France

Contacts

Primary ContactXavier ARGEMI, MD

xavier.argemi@chru-strasbourg.fr33 3 69 55 11 87

Outcome results